Article in Molecular cancer research : MCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Lily L Nguyen *Molecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado.ORCID 0000-0003-4425-2536
Zachary L Watson *Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-9425-1449
Raquel OrtegaMolecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado.ORCID 0000-0003-1954-0704
Elizabeth R WoodruffDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-0237-7453
Kimberly R JordanDepartment of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-8380-7157
Ritsuko IwanagaDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0008-1142-4753
Tomomi M YamamotoDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-6666-5406
Courtney A BaileyDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0003-0176-7601
Francis ToDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0008-5399-018X
Shujian LinDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0009-0004-0386-6480
Fabian R VillagomezDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-4510-1329
Abigail D JeongMolecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado.ORCID 0009-0000-1240-5898
Saketh R GuntupalliDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-2570-6635
Kian BehbakhtDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0003-4793-9958
Nausica ArnoultMolecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado.ORCID 0000-0003-2633-0270
Edward B ChuongMolecular Cellular Developmental Biology, The University of Colorado Boulder, Boulder, Colorado.ORCID 0000-0002-5392-937X
Benjamin G BitlerDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0002-5809-5271
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Transposon-mediated rewiring of gene regulatory networksR35GM128822 · NIGMS · UNIVERSITY OF COLORADO · PI Edward Bo-yi Chuong · 2018 to 2026
$3.5M
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparitiesR01CA285446 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler, Matthew J Sikora · 2023 to 2026
$2.4M
Targeting Wnt signaling in therapy-resistant ovarian cancerR37CA261987 · NCI · UNIVERSITY OF COLORADO DENVER · PI Benjamin G Bitler · 2021 to 2026
$2.4M
Deciphering the role of heterochromatin in telomere function and maintenance mechanismsR35GM143108 · NIGMS · UNIVERSITY OF COLORADO · PI ARNOULT, NAUSICA C. · 2021 to 2025
$1.9M
Deciphering the function of the APE2 nuclease during repair by alternative end-joining and its role in HR-deficient cellsR01CA266100 · NCI · UNIVERSITY OF COLORADO · PI Nausica C. Arnoult · 2022 to 2026
$1.7M
Targeting Wnt signaling to overcome PARP inhibitor resistance in ovarian cancerR00CA194318 · NCI · UNIVERSITY OF COLORADO DENVER · PI BITLER, BENJAMIN G · 2017 to 2019
$745k
Targeting histone methyltransferases EHMT1 and EHMT2 to sensitize PARP inhibitor-resistant ovarian cancerR03CA249571 · NCI · UNIVERSITY OF COLORADO DENVER · PI WATSON, ZACHARY LEVI · 2021 to 2022
$156k
All of Us Research Program (All of Us NIH) P30CA046934All of Us Research Program (All of Us NIH) R01CA266100All of Us Research Program (All of Us NIH) R35GM128822All of Us Research Program (All of Us NIH) R37CA261987American Cancer Society (ACS) RSG-19-129-01-DDCNCI NIH HHS P30 CA046934NCI NIH HHS R00 CA194318NCI NIH HHS R01 CA266100NCI NIH HHS R01 CA285446NCI NIH HHS R03 CA249571NCI NIH HHS R37 CA261987NIGMS NIH HHS R35 GM128822NIGMS NIH HHS R35 GM143108US Department of Defense OC200225US Department of Defense OC200302US Department of Defense OC210257U.S. Department of Defense (DOD) OC170228
6 · The paper itself
Abstract
Poly ADP-ribose polymerase inhibitors (PARPi) are first-line maintenance therapy for ovarian cancer and an alternative therapy for several other cancer types. However, PARPi-resistance is rising, and there is currently an unmet need to combat PARPi-resistant tumors. Here, we created an immunocompetent, PARPi-resistant mouse model to test the efficacy of combinatory PARPi and euchromatic histone methyltransferase 1/2 inhibitor (EHMTi) in the treatment of PARPi-resistant ovarian cancer. We discovered that inhibition of EHMT1/2 resensitizes cells to PARPi. Markedly, we show that single EHMTi and combinatory EHMTi/PARPi significantly reduced PARPi-resistant tumor burden and that this reduction is partially dependent on CD8 T cells. Altogether, our results show a low-toxicity drug that effectively treats PARPi-resistant ovarian cancer in an immune-dependent manner, supporting its entry into clinical development and potential incorporation of immunotherapy. Implications: Targeting the epigenome of therapy-resistant ovarian cancer induces an antitumor response mediated in part through an antitumor immune response.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. · full record | OpenQuestion